Canada markets closed

Xtant Medical Holdings, Inc. (XTNT)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.8610-0.0336 (-3.76%)
At close: 03:59PM EDT
0.8782 +0.02 (+2.00%)
After hours: 05:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8946
Open0.8900
Bid0.8600 x 900
Ask0.9650 x 800
Day's Range0.8520 - 0.9420
52 Week Range0.6000 - 1.4500
Volume27,619
Avg. Volume152,716
Market Cap112.117M
Beta (5Y Monthly)0.22
PE Ratio (TTM)86.10
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds

    BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™. “The launches of SimpliGraft and SimpliMax highlights the strength of our newly revitalized Research and Development team,” said Sean Browne, President and CEO of Xtant Medical. “We

  • GlobeNewswire

    Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

    Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. “2023 was a transformative year for Xtant Medical. We achieved record annual revenues of $91.3 million, up 58% y

  • GlobeNewswire

    Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

    BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host